Search Results - "Fretland, J."

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results by Yap, Timothy A., Fontana, Elisa, Lee, Elizabeth K., Spigel, David R., Højgaard, Martin, Lheureux, Stephanie, Mettu, Niharika B., Carneiro, Benedito A., Carter, Louise, Plummer, Ruth, Cote, Gregory M., Meric-Bernstam, Funda, O’Connell, Joseph, Schonhoft, Joseph D., Wainszelbaum, Marisa, Fretland, Adrian J., Manley, Peter, Xu, Yi, Ulanet, Danielle, Rimkunas, Victoria, Zinda, Mike, Koehler, Maria, Silverman, Ian M., Reis-Filho, Jorge S., Rosen, Ezra

“…Predictive biomarkers of response are essential to effectively guide targeted cancer treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi)…”
Get full text

Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450 by YUAN CHEN, LILING LIU, NGUYEN, Khanh, FRETLAND, Adrian J

“…Reaction phenotyping using recombinant human cytochromes P450 (P450) has great utility in early discovery. However, to fully realize the advantages of using…”
Get full text

Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions by Chen, Yuan, Liu, Liling, Monshouwer, Mario, Fretland, Adrian J

“…Assessment of time-dependent inhibition (TDI), especially CYP3A4, is an important parameter for preclinical and clinical development. The use of human liver…”
Get full text

Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors by Pilla Reddy, Venkatesh, Fretland, Adrian J., Zhou, Diansong, Sharma, Shringi, Chen, Buyun, Vishwanathan, Karthick, McGinnity, Dermot F., Xu, Yan, Ware, Joseph A.

“…Purpose Limited information is available regarding the drug–drug interaction (DDI) potential of molecular targeted agents and rituximab plus cyclophosphamide,…”
Get full text

Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms by HEIN, D. W, DOLL, M. A, FRETLAND, A. J, LEFF, M. A, WEBB, S. J, XIAO, G. H, DEVANABOYINA, U.-S, NANGJU, N. A, YI FENG

“…The focus of this review is the molecular genetics, including consensus NAT1 and NAT2 nomenclature, and cancer epidemiology of the NAT1 and NAT2 acetylation…”
Get full text

Epoxide hydrolases: biochemistry and molecular biology by Fretland, Adrian J, Omiecinski, Curtis J

“…Epoxides are organic three-membered oxygen compounds that arise from oxidative metabolism of endogenous, as well as xenobiotic compounds via chemical and…”
Get full text

Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991 by Goliaei, Ardeshir, Woods, Haley A., Tron, Adriana E., Belmonte, Matthew A., Secrist, J. Paul, Ferguson, Douglas, Drew, Lisa, Fretland, Adrian J., Aldridge, Bree B., Gibbons, Francis D.

“…Anticancer efficacy is driven not only by dose but also by frequency and duration of treatment. We describe a multiscale model combining cell cycle, cellular…”
Get full text

Effects of single nucleotide polymorphisms in human N‐acetyltransferase 2 on metabolic activation (O‐acetylation) of heterocyclic amine carcinogens by Hein, David W., Fretland, Adrian J., Doll, Mark A.

“…N‐Acetyltransferase 2 (NAT2) catalyzes the O‐acetylation of N‐hydroxy heterocyclic amines such as N‐hydroxy‐2‐amino‐3,8‐dimethylimidazo[4,5‐f]quinoxaline…”
Get full text

Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades by Davies, Michael, Jones, Rhys D.O., Grime, Ken, Jansson-Löfmark, Rasmus, Fretland, Adrian J., Winiwarter, Susanne, Morgan, Paul, McGinnity, Dermot F.

“…During drug discovery and prior to the first human dose of a novel candidate drug, the pharmacokinetic (PK) behavior of the drug in humans is predicted from…”
Get full text

Sustained release and improved bioavailability in mice after subcutaneous administration of griseofulvin as nano- and microcrystals by Sigfridsson, Kalle, Xue, Aixiang, Goodwin, Kelly, Fretland, Adrian J., Arvidsson, Torbjörn

“…[Display omitted] The objective of the study was to evaluate the pharmacokinetic profile after different subcutaneous (s.c.) administrations of nano- and…”
Get full text

Tissue distribution of N-acetyltransferase 1 and 2 catalyzing the N-acetylation of 4-aminobiphenyl and O-acetylation of N-hydroxy-4-aminobiphenyl in the congenic rapid and slow acetylator Syrian hamster by Hein, David W., Doll, Mark A., Nerland, Donald E., Fretland, Adrian J.

“…N‐acetyltransferase 1 (NAT1) and 2 (NAT2) enzymes catalyzing both deactivation (N‐acetylation) and activation (O‐acetylation) of arylamine carcinogens such as…”
Get full text

Identification and Biosynthesis of an N-Glucuronide Metabolite of Camonsertib by Papp, Robert, Trimble, Laird, Fretland, Adrian J, Manohar, Ravi, Phipps, Richard, Kvaerno, Lisbet, Perryman, Alexander L, Reynolds, Gregory, Black, W Cameron

“…Camonsertib is a novel ATR kinase inhibitor in clinical development for advanced cancers targeting sensitizing mutations. This article describes the…”
Get full text

Development of a quantification method for adenosine in tumors by LC-MS/MS with dansyl chloride derivatization by Goodwin, Kelly J., Gangl, Eric, Sarkar, Ujjal, Pop-Damkov, Petar, Jones, Natalie, Borodovsky, Alexandra, Woessner, Richard, Fretland, Adrian J.

“…Adenosine is known to be an important signaling molecule in many physiological processes and has recently been shown to be an important molecule in oncology. A…”
Get full text

753 IMPACT OF LOW DOSE RITONAVIR BOOSTING ON THE PHARMACOKINETICS OF RG7227 (ITMN-191), A HIGHLY POTENT AND SELECTIVE INHIBITOR OF THE HCV NS3/4A PROTEASE by Haznedar, J.Ö, Fretland, J, Leong, G, Blotner, S, Hill, T, Smith, P, Tran, J.Q

Get full text

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib by Rosen, Ezra, Yap, Timothy A, Lee, Elizabeth K, Højgaard, Martin, Mettu, Niharika B, Lheureux, Stephanie, Carneiro, Benedito A, Plummer, Ruth, Fretland, Adrian J, Ulanet, Danielle, Xu, Yi, McDougall, Robin, Koehler, Maria, Fontana, Elisa

“…Camonsertib is a highly selective and potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. Dose-dependent anemia is a class-related…”
Get full text

Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study) by Fontana, Elisa, Rosen, Ezra, Lee, Elizabeth K, Højgaard, Martin, Mettu, Niharika B, Lheureux, Stephanie, Carneiro, Benedito A, Cote, Gregory M, Carter, Louise, Plummer, Ruth, Mahalingam, Devalingam, Fretland, Adrian J, Schonhoft, Joseph D, Silverman, Ian M, Wainszelbaum, Marisa, Xu, Yi, Ulanet, Danielle, Koehler, Maria, Yap, Timothy A

“…Abstract Background Camonsertib is a selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with demonstrated efficacy in tumors with…”
Get full text

Dietary Selenium Reduces the Formation of Aberrant Crypts in Rats Administered 3,2′-Dimethyl-4-aminobiphenyl by Feng, Yi, Finley, John W., Davis, Cindy D., Becker, William K., Fretland, Adrian J., Hein, David W.

“…Human epidemiologic studies suggest that low selenium status is associated with increased cancer risk and that selenium supplementation is associated with…”
Get full text

Novel Human N-Acetyltransferase 2 Alleles That Differ in Mechanism for Slow Acetylator Phenotype by Leff, M A, Fretland, A J, Doll, M A, Hein, D W

“…Three novel human NAT2 alleles ( NAT2*5D , NAT2*6D , and NAT2*14G ) were identified and characterized in a yeast expression system. The common rapid ( NAT2*4 )…”
Get full text

Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes by Vasalou, Christina, Ferguson, Douglas, Li, Weimin, Muse, Victorine, Gibbons, Francis D, Sonzini, Silvia, Zhang, Guangnong, Pop-Damkov, Petar, Gangl, Eric, Balachander, Srividya B, Wen, Shenghua, Schuller, Alwin G, Puri, Sanyogitta, Mazza, Mariarosa, Ashford, Marianne, Fretland, Adrian J, McGinnity, Dermot F, Jones, Rhys D. O

“…A physiologically based pharmacokinetic model was developed to describe the tissue distribution kinetics of a dendritic nanoparticle and its conjugated active…”
Get full text

Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy by Williamson, Beth, Colclough, Nicola, Fretland, Adrian John, Jones, Barry Christopher, Jones, Rhys Dafydd Owen, McGinnity, Dermot Francis

“…DMPK data and knowledge are critical in maximising the probability of developing successful drugs via the application of in silico, in vitro and in vivo…”
Get more information